The Types segment classifies services by methodological approach, shaping the cost structure and technology adoption curve within the market. Cell‑based assays dominate, comprising roughly 42 % of service revenue, as they enable functional readouts for pharmacology and toxicology studies. Biochemical assays, which measure enzyme activity, receptor binding, or protein interactions, account for 26 % and are essential for mechanistic insights. Molecular assays—including PCR, qRT‑PCR, and next‑generation sequencing‑based tests—represent 17 % of the market, reflecting the rise of genomics‑driven research. High‑throughput screening (HTS) platforms, offering rapid compound profiling, contribute about 9 %, driven by the need for large‑scale library evaluation. Imaging assays, encompassing high‑content and live‑cell imaging, hold the remaining 6 %, providing spatial and temporal resolution for phenotypic analysis. This typology clarifies how each service category adds distinct value and collectively sustains the growth trajectory of the In Vitro Testing Service market.